Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New hope for advanced cancers: combo therapy trial launches

NCT ID NCT06953089

First seen Nov 01, 2025 · Last updated May 21, 2026 · Updated 33 times

Summary

This study tests two new drug combinations (DB-1311 with BNT327 or DB-1305) in adults with advanced or metastatic solid tumors that have not responded to standard treatments. The goal is to see if these combinations are safe and can shrink tumors. About 492 participants will take part in this Phase 2 trial.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SOLID TUMORS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • AUS04-0

    RECRUITING

    Birtinya, Queensland, 4575, Australia

  • AUS05-0

    RECRUITING

    Adelaide, South Australia, 5000, Australia

  • AUS06-0

    RECRUITING

    Benowa, Queensland, 4217, Australia

  • AUS07-0

    RECRUITING

    North Sydney, New South Wales, 2060, Australia

  • CHN01-0

    RECRUITING

    Shanghai, Shanghai Municipality, 200120, China

  • CHN02-0

    RECRUITING

    Beijing, Beijing Municipality, 100021, China

  • CHN04-0

    RECRUITING

    Hubei, Hubei, 430014, China

  • CHN04-0

    RECRUITING

    Shanghai, Shanghai Municipality, 200032, China

  • CHN06-0

    RECRUITING

    Henan, Henan, 450008, China

  • CHN11-0

    RECRUITING

    Changsha, Hunan, 410013, China

  • CHN12-0

    RECRUITING

    Xinxiang, Henan, 453100, China

  • CHN13-0

    RECRUITING

    Beijing, Beijing Municipality, 100032, China

  • CHN16-0

    RECRUITING

    Xuzhou, Jiangsu, 221000, China

  • CHN17-0

    RECRUITING

    Dongguan, Guangdong, 523000, China

  • CHN23-0

    RECRUITING

    Beijing, Beijing Municipality, 100142, China

  • CHN24-0

    RECRUITING

    Chengdu, Sichuan, 610041, China

  • CHN25-0

    RECRUITING

    Xi'an, Shaanxi, 710061, China

  • CHN26-0

    RECRUITING

    Wuhan, Hubei, 00000, China

  • CHN34-0

    RECRUITING

    Wuhan, Hubei, 430079, China

  • CHN35-0

    RECRUITING

    Shenyang, Liaoning, 110042, China

  • TWN01-0

    RECRUITING

    Taipei, Taipei, 0, Taiwan

  • TWN02-0

    RECRUITING

    Taipei, Taipei, 23561, Taiwan

  • USA01-0

    RECRUITING

    Wheat Ridge, Colorado, 80033, United States

  • USA03-0

    RECRUITING

    Charleston, South Carolina, 29425, United States

  • USA04-0

    RECRUITING

    New York, New York, 10032, United States

  • USA05-0

    RECRUITING

    Virginia Beach, Virginia, 22031, United States

  • USA06-0

    RECRUITING

    Los Angeles, California, 90025, United States

  • USA07-0

    RECRUITING

    Spokane, Washington, 99208, United States

  • USA08-0

    RECRUITING

    Florida City, Florida, 99208, United States

  • USA09-0

    RECRUITING

    Puyallup, Washington, 98373, United States

  • USA10-0

    RECRUITING

    Atlanta, Georgia, 30318, United States

  • USA11-0

    RECRUITING

    Bethesda, Maryland, 20817, United States

  • USA12-0

    RECRUITING

    Houston, Texas, 77030, United States

  • USA13-0

    RECRUITING

    Anderson, Texas, 46011, United States

  • USA14-0

    RECRUITING

    Lincoln, Nebraska, 68506, United States

  • USA15-0

    RECRUITING

    Portland, Oregon, 97239, United States

  • USA16-0

    RECRUITING

    Los Angeles, California, 90025, United States

Conditions

Explore the condition pages connected to this study.